Healthcare
Treace Medical Concepts, Inc.(TMCI)
Live Price
Offline$4.23
+13.40% today
1Y Change
-31.71%
Window
Jun 23, 2025 โ Jun 15, 2026
- Market Cap
- $120.00M
- Revenue Growth
- +1.6%
- EPS Growth
- -3.3%
- Dividend Yield
- 0.0%
Coverage: 246 bars ยท Jun 23, 2025 โ Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Treace Medical Concepts, Inc. (TMCI) is a Healthcare stock with a market cap of $120.00M and listed on NASDAQ. The stock last traded around $4.23 and down 31.7% across the available one-year price window (Jun 23, 2025 โ Jun 15, 2026). Baseline metrics include revenue growth of +1.6%, EPS growth of -3.3%, a dividend yield of 0.0%. What stands out right now is revenue +1.6%, EPS -3.3%, free cash flow +39.5% with operating margin -25.5% and ROIC -33.9%. Valuation is more restrained than many high-expectation growth names at price/sales 0.6. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines TMCI price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+1.6% vs +7.6% peer median
Operating Margin
Below sector median
-25.5% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report landed above expectations
2026 was reported on May 8, 2026 with an EPS surprise of +9.7% and a revenue surprise of +2.7%.
The operating picture looks softer than before
Revenue is at +1.6% and EPS is at -3.3%, with operating margin around -25.5%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 6, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -13.5% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 8, 2026 | +9.7% | -3.5% | +32.3% | +75.6% |
2026 Feb 27, 2026 | +21.0% | -10.8% | -23.1% | -34.4% |
2025 Nov 6, 2025 | +7.1% | -28.3% | -49.6% | -56.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TMCI
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
TMCI Max Drawdown
-84.42%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for TMCI and SPY.
Company Overview
Treace Medical Concepts, Inc.
NASDAQ Global Select
Treace Medical Concepts, Inc., an orthopedic medical device company, engages in the design, manufacture, and marketing of medical devices for foot and ankle surgeons in the United States. It offers Lapiplasty procedure that allows podiatric surgeons to treat all three dimensions of the bunion, providing patients with a cosmetic and medical improvement. The company also provides Lapiplasty Mini-Incision precision system. In addition, it offers products to address ancillary surgical procedures, including akin osteotomies, weil osteotomies, intercuneiform stabilization, lesser tarsometatarsal joint fusions, and autograft bone harvesting, as well as for MTP fusion. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra Beach, Florida.
- Leadership
- John T. Treace
- IPO Date
- Apr 23, 2021
- Employees
- 477
- Street Address
- 203 Fort Wade Road
- Mailing
- Ponte Vedra, FL, 32081
- Region
- Ponte Vedra, FL, US
- Reporting Currency
- USD
- Investor Line
- 904 373 5940
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 0.6
- Price/Book
- 1.4
Growth
- Revenue
- +1.6%
- EPS
- -3.3%
- Free Cash Flow
- +39.5%
Profitability
- Gross Margin
- 79.8%
- Operating Margin
- -25.5%
- Net Margin
- -27.7%
- ROE
- -62.2%
- ROIC
- -33.9%
Balance Sheet
- Debt/Equity
- 0.16
- Current Ratio
- 4.31
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.